|
1
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Center MM, Jemal A and Ward E:
International trends in colorectal cancer incidence rates. Cancer
Epidemiol Biomarkers Prev. 18:1688–1694. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Merla A and Goel S: Novel drugs targeting
the epidermal growth factor receptor and its downstream pathways in
the treatment of colorectal cancer: A systematic review. Chemother
Res Pract. 2012:3871722012.PubMed/NCBI
|
|
7
|
Perkins G and Laurent-Puig P: Colorectal
cancer biology. Rev Prat. 65:802–806. 2015.(In French). PubMed/NCBI
|
|
8
|
Zeng Y, Xie H, Qiao Y, Wang J, Zhu X, He
G, Li Y, Ren X, Wang F, Liang L and Ding Y: FMNL2 regulates
Rho/ROCK pathway to promote actin assembly and cell invasion of
colorectal cancer. Cancer Sci. 106:1385–1393. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang X, Tan J, Li J, Kivimäe S, Yang X,
Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, et al: DACT3 is an
epigenetic regulator of Wnt/beta-catenin signaling in colorectal
cancer and is a therapeutic target of histone modifications. Cancer
Cell. 13:529–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meek DW: Regulation of the p53 response
and its relationship to cancer. Biochem J. 469:325–346. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basmadjian C, Zhao Q, Bentouhami E, Djehal
A, Nebigil CG, Johnson RA, Serova M, de Gramont A, Faivre S,
Raymond E and Désaubry LG: Cancer wars: Natural products strike
back. Front Chem. 2:202014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu CX, Yin QQ, Zhou HC, Wu YL, Pu JX, Xia
L, Liu W, Huang X, Jiang T, Wu MX, et al: Adenanthin targets
peroxiredoxin I and II to induce differentiation of leukemic cells.
Nat Chem Biol. 8:486–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun HD, Huang SX and Han QB: Diterpenoids
from Isodon species and their biological activities. Nat Prod Rep.
23:673–698. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ye H, Liang NC and Zheng XB: Progress in
research on anti-tumor effect of 5F isolated from Pteris
semipinnata L. Nat Pro Res Dev. 26:2082–2087. 2014.
|
|
17
|
Schubert WM and Sweeney WA: The effect of
ring strain on the ultraviolet spectra of α,β-unsaturated carbonyl
compounds. J Am Chem Soc. 77:2297–2300. 1955. View Article : Google Scholar
|
|
18
|
Wang F, Li YJ, Ren FC, Wei GZ and Liu JK:
Pterisolic acids A-F, new ent-kaurane diterpenoids from the fern
Pteris semipinnata. Chem Pharm Bull (Tokyo). 59:484–487. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hutchison M, Lewer P and MacMillan J:
Carbon-13 nuclear magnetic resonance spectra of eighteen
derivatives of ent-kaur-16-en-19-oic acid. J Chem Soc, Perkin
Trans. 1:2363–2366. 1984. View Article : Google Scholar
|
|
20
|
Santos HS, Barros FW, Albuquerque MR,
Bandeira PN, Pessoa C, Braz-Filho R, Monte FJ, Leal-Cardoso JH and
Lemos TL: Cytotoxic diterpenoids from Croton argyrophylloides. J
Nat Prod. 72:1884–1887. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ye Q, Yao G, Zhang M, Guo G, Hu Y, Jiang
J, Cheng L, Shi J, Li H, Zhang Y and Liu H: A novel ent-kaurane
diterpenoid executes antitumor function in colorectal cancer cells
by inhibiting Wnt/β-catenin signaling. Carcinogenesis. 36:318–326.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li X, Pu J, Jiang S, Su J, Kong L, Mao B,
Sun H and Li Y: Henryin, an ent-kaurane diterpenoid, inhibits Wnt
signaling through interference with β-catenin/TCF4 interaction in
colorectal cancer cells. PLoS One. 8:e685252013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu C, Li Y, Semenov M, Han C, Baeg GH,
Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin
phosphorylation/degradation by a dual-kinase mechanism. Cell.
108:837–847. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jin Y, Kanno T and Nishizaki T: Acute
restraint stress impairs induction of long-term potentiation by
activating GSK-3β. Neurochem Res. 40:36–40. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aschenbach WG, Ho RC, Sakamoto K, Fujii N,
Li Y, Kim YB, Hirshman MF and Goodyear LJ: Regulation of
dishevelled and beta-catenin in rat skeletal muscle: An alternative
exercise-induced GSK-3beta signaling pathway. Am J Physiol
Endocrinol Metab. 291:E152–E158. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim S, Lee J, Park J and Chung J: BP75,
bromodomain-containing M(r) 75,000 protein, binds dishevelled-1 and
enhances Wnt signaling by inactivating glycogen synthase kinase-3
beta. Cancer Res. 63:4792–4795. 2003.PubMed/NCBI
|
|
27
|
Gao C and Chen YG: Dishevelled: The hub of
Wnt signaling. Cell Signal. 22:717–727. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liao YJ, Bai HY, Li ZH, Zou J, Chen JW,
Zheng F, Zhang JX, Mai SJ, Zeng MS, Sun HD, et al: Longikaurin A, a
natural ent-kaurane, induces G2/M phase arrest via downregulation
of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in
hepatocellular carcinoma cells. Cell Death Dis. 5:e11372014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weng W, Feng J, Qin H and Ma Y: Molecular
therapy of colorectal cancer: Progress and future directions. Int J
Cancer. 136:493–502. 2015.PubMed/NCBI
|
|
30
|
Zhang X and Hao J: Development of
anticancer agents targeting the Wnt/β-catenin signaling. Am J
Cancer Res. 5:2344–2360. 2015.PubMed/NCBI
|
|
31
|
Bi X, Xia X, Mou T, Jiang B, Fan D, Wang
P, Liu Y, Hou Y and Zhao Y: Anti-tumor activity of three
ginsenoside derivatives in lung cancer is associated with
Wnt/β-catenin signaling inhibition. Eur J Pharmacol. 742:145–152.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Albring KF, Weidemuller J, Mittag S,
Weiske J, Friedrich K, Geroni MC, Lombardi P and Huber O: Berberine
acts as a natural inhibitor of Wnt/β-catenin
signaling-identification of more active 13-arylalkyl derivatives.
Biofactors. 39:652–662. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee MA, Kim WK, Park HJ, Kang SS and Lee
SK: Anti-proliferative activity of hydnocarpin, a natural lignan,
is associated with the suppression of Wnt/β-catenin signaling
pathway in colon cancer cells. Bioorg Med Chem Lett. 23:5511–5514.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Choi H, Gwak J, Cho M, Ryu MJ, Lee JH, Kim
SK, Kim YH, Lee GW, Yun MY, Cuong NM, et al: Murrayafoline A
attenuates the Wnt/beta-catenin pathway by promoting the
degradation of intracellular beta-catenin proteins. Biochem Biophys
Res Commun. 391:915–920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tarapore RS, Siddiqui IA and Mukhtar H:
Modulation of Wnt/β-catenin signaling pathway by bioactive food
components. Carcinogenesis. 33:483–491. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bai L and Wang S: Targeting apoptosis
pathways for new cancer therapeutics. Annu Rev Med. 65:139–155.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun SY, Hail N Jr and Lotan R: Apoptosis
as a novel target for cancer chemoprevention. J Natl Cancer Inst.
96:662–672. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kucharczak J, Simmons MJ, Fan Y and
Gelinas C: To be, or not to be: NF-kappaB is the answer-role of
Rel/NF-kappaB in the regulation of apoptosis. Oncogene.
22:8961–8982. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin A and Karin M: NF-kappaB in cancer: A
marked target. Semin Cancer Biol. 13:107–114. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li XL, Zhou J, Chen ZR and Chng WJ: P53
mutations in colorectal cancer-molecular pathogenesis and
pharmacological reactivation. World J Gastroenterol. 21:84–93.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dashzeveg N and Yoshida K: Cell death
decision by p53 via control of the mitochondrial membrane. Cancer
Lett. 367:108–112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang J and Yi J: Cancer cell killing via
ROS: To increase or decrease, that is the question. Cancer Biol
Ther. 7:1875–1884. 2008. View Article : Google Scholar : PubMed/NCBI
|
